↓ Skip to main content

HIV-associated Kaposi’s sarcoma in Maputo, Mozambique: outcomes in a specialized treatment center, 2010–2015

Overview of attention for article published in Infectious Agents and Cancer, January 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#31 of 387)
  • High Attention Score compared to outputs of the same age (82nd percentile)

Mentioned by

1 news outlet


9 Dimensions

Readers on

41 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
HIV-associated Kaposi’s sarcoma in Maputo, Mozambique: outcomes in a specialized treatment center, 2010–2015
Published in
Infectious Agents and Cancer, January 2018
DOI 10.1186/s13027-018-0177-6
Pubmed ID

Vini Fardhdiani, Lucas Molfino, Ana Gabriela Zamudio, Rolanda Manuel, Gilda Luciano, Iza Ciglenecki, Barbara Rusch, Laurence Toutous Trellu, Matthew E Coldiron


Kaposi's sarcoma (KS) is a common HIV-associated malignancy associated with disability, pain and poor outcomes. The cornerstone of its treatment is antiretroviral therapy, but advanced disease necessitates the addition of chemotherapy. In high-income settings, this often consists of liposomal anthracyclines, but in Mozambique, the first line includes conventional doxorubicin, bleomycin and vincristine, which is poorly-tolerated. Médecins Sans Frontières supports the Ministry of Health (MOH) in a specialized HIV and KS treatment center at the Centro de Referencia de Alto Maé in Maputo. We performed a retrospective analysis of data collected on patients enrolled at the CRAM between 2010 and 2015, extracting routinely-collected clinical information from patient care databases. KS treatment followed national guidelines, and KS staging followed AIDS Clinical Trials Group and MOH criteria. Baseline description of the cohort and patient outcomes was performed. Risk factors for negative outcomes (death or loss to follow-up) were explored using Cox regression. Between 2010 and 2015, 1573 patients were enrolled, and 1210 began chemotherapy. A majority were young adult males. At enrollment, CD4 was < 200 cells/μl in 45% of patients. Among patients receiving chemotherapy, 78% received combination doxorubicin-bleomycin-vincristine. Among patients receiving chemotherapy, 43% were lost to follow-up and 8% were known to have died. In multivariate regression, the only risk factors identified with poor outcomes were CD4 < 100 cells/μl at enrollment (Risk ratio 1.5, 95%CI 1.1-2.1, p = 0.02 and having S1 disease (RR 1.7, 95%CI 1.2-2.3, p = 0.001). We describe a large cohort of patients receiving care for HIV-associated KS in a specialized clinic in an urban setting. Outcomes were nonetheless unsatisfactory. Efforts should be made to decrease late referrals and entry into care and to increase access to more effective and better-tolerated treatments like liposomal doxorubicin.

Mendeley readers

The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 41 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 8 20%
Student > Ph. D. Student 7 17%
Other 5 12%
Researcher 5 12%
Lecturer 2 5%
Other 4 10%
Unknown 10 24%
Readers by discipline Count As %
Medicine and Dentistry 15 37%
Nursing and Health Professions 6 15%
Biochemistry, Genetics and Molecular Biology 2 5%
Business, Management and Accounting 1 2%
Agricultural and Biological Sciences 1 2%
Other 3 7%
Unknown 13 32%

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 July 2019.
All research outputs
of 16,669,654 outputs
Outputs from Infectious Agents and Cancer
of 387 outputs
Outputs of similar age
of 371,323 outputs
Outputs of similar age from Infectious Agents and Cancer
of 1 outputs
Altmetric has tracked 16,669,654 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 387 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 371,323 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them